X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs SUN PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER SUN PHARMA PFIZER/
SUN PHARMA
 
P/E (TTM) x 36.1 38.3 94.1% View Chart
P/BV x 5.3 4.1 129.8% View Chart
Dividend Yield % 0.6 0.3 207.9%  

Financials

 PFIZER   SUN PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-18
SUN PHARMA
Mar-18
PFIZER/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,365701 337.6%   
Low Rs1,625433 375.1%   
Sales per share (Unadj.) Rs430.3110.4 389.7%  
Earnings per share (Unadj.) Rs78.711.0 717.0%  
Cash flow per share (Unadj.) Rs93.217.2 540.9%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %1.00.4 284.1%  
Book value per share (Unadj.) Rs586.5158.8 369.3%  
Shares outstanding (eoy) m45.752,399.26 1.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.65.1 90.3%   
Avg P/E ratio x25.351.6 49.1%  
P/CF ratio (eoy) x21.432.9 65.1%  
Price / Book Value ratio x3.43.6 95.3%  
Dividend payout %25.418.2 139.5%   
Avg Mkt Cap Rs m91,2711,360,021 6.7%   
No. of employees `0002.617.8 14.8%   
Total wages/salary Rs m3,14353,671 5.9%   
Avg. sales/employee Rs Th7,484.814,890.9 50.3%   
Avg. wages/employee Rs Th1,195.03,017.1 39.6%   
Avg. net profit/employee Rs Th1,369.11,480.6 92.5%   
INCOME DATA
Net Sales Rs m19,685264,895 7.4%  
Other income Rs m1,1438,388 13.6%   
Total revenues Rs m20,828273,282 7.6%   
Gross profit Rs m5,00356,081 8.9%  
Depreciation Rs m66314,998 4.4%   
Interest Rs m45,176 0.1%   
Profit before tax Rs m5,47944,295 12.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m1,8788,452 22.2%   
Profit after tax Rs m3,60126,338 13.7%  
Gross profit margin %25.421.2 120.0%  
Effective tax rate %34.319.1 179.7%   
Net profit margin %18.39.9 184.0%  
BALANCE SHEET DATA
Current assets Rs m24,167316,359 7.6%   
Current liabilities Rs m9,544198,643 4.8%   
Net working cap to sales %74.344.4 167.2%  
Current ratio x2.51.6 159.0%  
Inventory Days Days5595 58.1%  
Debtors Days Days29108 26.7%  
Net fixed assets Rs m9,514213,178 4.5%   
Share capital Rs m4582,399 19.1%   
"Free" reserves Rs m26,375378,606 7.0%   
Net worth Rs m26,832381,006 7.0%   
Long term debt Rs m2517,721 0.1%   
Total assets Rs m36,900643,028 5.7%  
Interest coverage x1,305.59.6 13,658.9%   
Debt to equity ratio x00 2.0%  
Sales to assets ratio x0.50.4 129.5%   
Return on assets %9.84.9 199.3%  
Return on equity %13.46.9 194.1%  
Return on capital %20.410.0 203.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2240,816 0.1%   
Fx outflow Rs m1,48930,143 4.9%   
Net fx Rs m-1,46610,673 -13.7%   
CASH FLOW
From Operations Rs m3,31839,072 8.5%  
From Investments Rs m-2,383-33,708 7.1%  
From Financial Activity Rs m-1,104-15,393 7.2%  
Net Cashflow Rs m-169-7,359 2.3%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 5.1 146.2%  
FIIs % 4.9 23.0 21.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 8.3 285.5%  
Shareholders   85,207 133,026 64.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, IPO Buzz, and Top Stocks in Action Today(Pre-Open)

On Wednesday, share markets in India witnessed volatile trading activity and ended on a negative note. Among sectoral indices, FMCG stocks and realty stocks lost the most.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 19, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS